278 related articles for article (PubMed ID: 23520479)
1. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines.
Zhang X; Liu G; Kang Y; Dong Z; Qian Q; Ma X
PLoS One; 2013; 8(3):e57692. PubMed ID: 23520479
[TBL] [Abstract][Full Text] [Related]
2. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Ahmad A; Maitah MY; Ginnebaugh KR; Li Y; Bao B; Gadgeel SM; Sarkar FH
J Hematol Oncol; 2013 Oct; 6(1):77. PubMed ID: 24199791
[TBL] [Abstract][Full Text] [Related]
4. Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC.
Iderzorig T; Kellen J; Osude C; Singh S; Woodman JA; Garcia C; Puri N
Biochem Biophys Res Commun; 2018 Feb; 496(2):770-777. PubMed ID: 29337056
[TBL] [Abstract][Full Text] [Related]
5. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.
Rastogi I; Rajanna S; Webb A; Chhabra G; Foster B; Webb B; Puri N
Biochem Biophys Res Commun; 2016 Sep; 477(4):937-944. PubMed ID: 27396618
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
Abera MB; Kazanietz MG
Mol Pharmacol; 2015 May; 87(5):832-41. PubMed ID: 25724832
[TBL] [Abstract][Full Text] [Related]
8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
9. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Morgillo F; Cascone T; D'Aiuto E; Martinelli E; Troiani T; Saintigny P; De Palma R; Heymach JV; Berrino L; Tuccillo C; Ciardiello F
Br J Cancer; 2011 Jul; 105(3):382-92. PubMed ID: 21750552
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
11. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
12. Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.
Mizuuchi H; Suda K; Sato K; Tomida S; Fujita Y; Kobayashi Y; Maehara Y; Sekido Y; Nishio K; Mitsudomi T
PLoS One; 2015; 10(4):e0123901. PubMed ID: 25875914
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Chung JH; Rho JK; Xu X; Lee JS; Yoon HI; Lee CT; Choi YJ; Kim HR; Kim CH; Lee JC
Lung Cancer; 2011 Aug; 73(2):176-82. PubMed ID: 21168239
[TBL] [Abstract][Full Text] [Related]
14. Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.
Haddad Y; Choi W; McConkey DJ
Clin Cancer Res; 2009 Jan; 15(2):532-42. PubMed ID: 19147758
[TBL] [Abstract][Full Text] [Related]
15. Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
Ghosh G; Lian X; Kron SJ; Palecek SP
BMC Cancer; 2012 Mar; 12():95. PubMed ID: 22433462
[TBL] [Abstract][Full Text] [Related]
16. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Yoshida T; Song L; Bai Y; Kinose F; Li J; Ohaegbulam KC; Muñoz-Antonia T; Qu X; Eschrich S; Uramoto H; Tanaka F; Nasarre P; Gemmill RM; Roche J; Drabkin HA; Haura EB
PLoS One; 2016; 11(1):e0147344. PubMed ID: 26789630
[TBL] [Abstract][Full Text] [Related]
17. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
[TBL] [Abstract][Full Text] [Related]
18. GBP1 promotes erlotinib resistance via PGK1‑activated EMT signaling in non‑small cell lung cancer.
Cheng L; Gou L; Wei T; Zhang J
Int J Oncol; 2020 Sep; 57(3):858-870. PubMed ID: 32582960
[TBL] [Abstract][Full Text] [Related]
19. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
Liu C; Shaurova T; Shoemaker S; Petkovich M; Hershberger PA; Wu Y
Mol Pharm; 2018 Aug; 15(8):3216-3226. PubMed ID: 29902012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
